Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.
- DOI
- 10.1016/s1470-2045(25)00287-6
- Published
- 2025 Jul
- Container
- The Lancet. Oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s1470-2045-25-00287-6,
title = {Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.},
author = {Elimova E and Ajani J and Burris H and Denlinger CS and Iqbal S and Kang YK and Kim JH and Lee KW and Lin B and Mehta R and Oh DY and Rha SY and Seol YM and Yang L and Ozog MA and Garfin PM and Ku G},
year = {2025},
journal = {The Lancet. Oncology},
doi = {10.1016/s1470-2045(25)00287-6},
url = {https://doi.org/10.1016/s1470-2045(25)00287-6}
}RIS
TY - JOUR TI - Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study. AU - Elimova E AU - Ajani J AU - Burris H AU - Denlinger CS AU - Iqbal S AU - Kang YK AU - Kim JH AU - Lee KW AU - Lin B AU - Mehta R AU - Oh DY AU - Rha SY AU - Seol YM AU - Yang L AU - Ozog MA AU - Garfin PM AU - Ku G PY - 2025 JO - The Lancet. Oncology DO - 10.1016/s1470-2045(25)00287-6 UR - https://doi.org/10.1016/s1470-2045(25)00287-6 ER -
APA
E, E., J, A., H, B., CS, D., S, I., YK, K., JH, K., KW, L., B, L., R, M., DY, O., SY, R., YM, S., L, Y., MA, O., PM, G., & G, K. (2025). Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(25)00287-6
Source records
- pubmed · retrieved 2026-09-26T05:17:04.809Z